This material has been prepared for marketing purposes. The full terms and conditions of the warrant and more information about the company have been reported on the company's warrant page. https://www.to3.alzinova.com/
Alzinova is developing two treatments for the chronic neurodegenerative disease Alzheimer's. One is the disease-modifying vaccine ALZ-101 which is in clinical phase Ib, and the monoclonal antibody ALZ-201 which is in the preclinical development phase.
The company specifically targets the toxic accumulations of amyloid-beta in the form of oligomers, which the company believes is a strategy that differs from other drug candidates in clinical development.
Milestone achieved in the Phase Ib study
Since Alzinova initiated its clinical trial with the candidate ALZ-101 in late fall 2021, development has progressed rapidly, especially in recent months. By the end of 2022, all patients had been recruited to the study and received a first dose. Four months later, all 26 participants in the study had received their final dose of ALZ-101 or placebo.
The company also received approval to initiate an extension of the study. A first interim analysis of study data points to good safety and tolerability, as well as indications of an immunological response. Read more.
Redemption of warrants of series TO3
With a view to the next milestone in the development work, Alzinova is now in the process of redeeming the TO3 warrant. The redemption period began on April 11, 2023, and will run until April 25.
The subscription price is SEK 2,17 per share, which if fully exercised could bring the company up to approximately SEK 28,1 million. Read more on the company's website.
CEO responds
BioStock contacted the CEO Kristina Torfgard for some questions about what redemption means for Alzinova.
Kristina, to begin with, what distinguishes your candidate ALZ-101 from others under development?
– A vaccination with ALZ-101 means that the body generates its own antibodies, specific against toxic accumulations of amyloid-beta oligomers in the brain.
– It therefore differs from other candidates under development, but also from the first approved drugs, which are antibody treatments where the antibodies attack larger aggregated forms of amyloid-beta, known as plaques. However, the plaques contain both toxic and harmless protein, which can lead to serious side effects and a limited effect. Simply put, our goal is to only neutralize the toxic substances in the brain, while protecting the synapses and keeping healthy cells intact.
– In addition, our vaccine candidate can be given significantly less frequently than other drug candidates under development. This could contribute to better health economics for both the patient and society. At the same time, it could make it possible for more people to have access to effective Alzheimer's treatment.
What is happening right now in the Phase Ib study?
– The last patient has recently received their fourth and final dose. We are now planning a second interim analysis to further inform us about safety and tolerability, as well as immune response.
– Getting data from the patients in our study that shows that the body produces its own antibodies specific to amyloid-beta would therefore be optimal. At the same time, we are also planning an extension of the study and we recently received regulatory approval to conduct one.
Finally, what does the redemption of TO3 mean for Alzinova?
– I believe that we have a stable and financially sound situation, where this capital can further strengthen the cash flow ahead of the planned extension of the phase Ib study. With these funds, we can also continue to carry out preparations for phase II and continue with the work to develop ALZ-201 in order to eventually take it into clinical development.
– According to analysts, annual sales of disease-modifying drugs for Alzheimer's will amount to $13 billion in 2028. So, while we feel a clear calling to help this vulnerable patient group, it should also be borne in mind that the potential monetary return could be significant if our clinical studies turn out well.
– With the capital from the warrants, we look forward to new advances and continued development of our drug candidates in the fight against Alzheimer's disease and to launching them on the market in the future. I welcome both existing and new shareholders to join us on this journey.
The content of the article is sponsored by the company in question that appears in the text. BioStock does not provide investment advice and does not mediate any investment orders. BioStock takes no responsibility for actions and/or any loss or damage based on the use of content published on BioStock.se. Instead, each investment decision is made independently by the individual investor.